A team of researchers from the USA has found that adding a certain adjuvant therapy to aVaccine the ability to combat multiple virus strainsincreased. In their paper published in the journal Science, the group describes using lipids to encapsulate the adjuvant so that alveolar macrophages can recognize it. Susanne Herold and Leif-Erik Sander from the Universities of Gießen and Marburg Lung Cancer, as well as the Berlin Institute of Health, published an article describing the team's work in the same journal issue.
Adjuvant therapy as an agent against viruses
In the current vaccine creation strategy, health officials in several countries are studying outbreak patterns of different strains. They then develop vaccines against those most likely to experience an outbreak in a given country. Scientists can repeat the process seasonally, with pharmaceuticals producing new vaccines every year.
Scientists have developed active droplets that can be used in long-lasting and precise dosage of medication.
What would be better, of course, is a single vaccine to prevent outbreaks of all strains that could pose a threat. Such a vaccine is not yet available, but scientists are working hard to develop one. In this new effort, researchers are one step closer to a new approach to using an inactivated virus. This allows them to trigger the immune system to activate a stronger immune response. Normally this would only happen when the body detects a strain of the virus. So far it has worked as planned on mice and ferrets.
The new approach involved combining an inactivated virus with 2′, 3′-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). This is a known activator of the immune response. To prevent the body from overreacting, the researchers covered it with a lipid made from a surfactant.
According to the researchers, the two components are:Studythen mixed into a nasal spray. Using this approach, the researchers found that the PS-GAMP nanoparticles were grown into alveolar macrophages, which then transferred them to and activated an innate immune sensor stimulator of interferon genes. This enabled the immune system to better defend itself against all five flu strains tested.
